WallStreetZenWallStreetZen

NASDAQ: BDRX
Biodexa Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Biodexa Pharmaceuticals revenue was $0.00 for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BDRX annual revenue was $0.0, with -100% growth year-over-year.

BDRX past revenue growth

How has BDRX's revenue growth performed historically?

Company
-100%
Industry
497.69%
Market
20.68%
BDRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
BDRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
BDRX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

BDRX revenue history

Current Revenue
$0.0
Current Earnings
-$7.2M
Current Profit Margin
0%

Be the first to know when BDRX announces revenue.

BDRX Revenue History By Year

BDRX Yearly RevenueBDRX RevenueBDRX ChangeBDRX Revenue Growth
2024-12-31$0.00-$482.28k-100.00%
2023-12-31$482.28k-$359.89k-42.73%
2022-12-31$842.17k$71.50k+9.28%
2021-12-31$770.67k$300.80k+64.02%
2020-12-31$469.86k-$416.98k-47.02%
2019-12-31$886.84k-$1.57M-63.94%
2018-12-31$2.46M$1.12M+84.02%
2017-12-31$1.34M-$296.85k-18.17%
2016-12-31$1.63M-$394.69k-19.46%
2015-12-31$2.03M$1.78M+729.29%
2014-12-31$244.55k$1.17k+0.48%
2013-12-31$243.38kN/AN/A

1 of 1

Biodexa Pharmaceuticals Revenue FAQ

What was BDRX's revenue last quarter?

Biodexa Pharmaceuticals (NASDAQ: BDRX) reported Q4 2024 revenue of N/A up N/A year over year. In the same quarter last year, Biodexa Pharmaceuticals's revenue was N/A.

What was Biodexa Pharmaceuticals's revenue in 2024?

Biodexa Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $0.00, a 100% decrease year over year.

How much does Biodexa Pharmaceuticals make in a day?

Based on Biodexa Pharmaceuticals annual revenue for the past five years, BDRX makes an average of $1,405.47 per day.

What was Biodexa Pharmaceuticals's annual revenue growth in the past year?

As of Q2 2025, Biodexa Pharmaceuticals's revenue has grown -100% year over year. This is 597.69 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Biodexa Pharmaceuticals's revenue in the past year totaled $0.00.

How much does Biodexa Pharmaceuticals make in a year?

Biodexa Pharmaceuticals's revenue by year for the past five years is:
  • Biodexa Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $0.00, a 100% decrease year over year.
  • Biodexa Pharmaceuticals's annual revenue for Dec 31, 2023 was $482.28 thousand, a 42.73% decrease from 2022.
  • Biodexa Pharmaceuticals's annual revenue for 2022 was $842.17 thousand, a 9.28% increase from 2021.
  • Biodexa Pharmaceuticals's annual revenue for 2021 was $770.67 thousand, a 64.02% increase from 2020.
  • Biodexa Pharmaceuticals's annual revenue for 2020 was $469.86 thousand, a 47.02% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.